Shots:
- NVIDIA reports that it is building the “Cambridge-1” supercomputer, which will be an NVIDIA DGX SuperPOD system capable of delivering 400+ petaflops of AI performance and 8 petaflops of Linpack performance and 1s expected to come online by the end of 2020
- GSK and AstraZeneca will be the first company to harness Cambridge-1 for research. Additionally, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, and Oxford Nanopore Technologies also plan to take advantage of the system
- Cambridge-1 will be the first NVIDIA supercomputer designed and built for external research access and will provide researchers and academics the ability to tackle challenging AI training, inference, and data science workloads at scale. NVIDIA will invest ~ $51.7M in Cambridge-1
Click here to read full press release/ article | Ref: NVIDIA | Image: Medsmart App
The post GSK and AstraZeneca Plan to Deploy NVIDIA’s Supercomputer for Drug Development first appeared on PharmaShots.
